What the Evidence Really Shows About Cannabis and Amyloidosis
Amyloidosis is a group of rare disorders in which misfolded proteins accumulate in tissues and organs. Depending on the type, deposits can damage the heart, kidneys, liver, nerves, digestive tract and other parts of the body. Because different forms of amyloidosis require different treatments, accurate diagnosis and amyloid typing are essential. The Mayo Clinic’s overview of amyloidosis diagnosis and treatment describes the condition’s varied causes, testing methods and treatment options.
Medical cannabis is sometimes discussed as a possible way to ease symptoms such as pain, nausea, poor appetite, anxiety or sleep problems. However, there is currently no strong clinical evidence that cannabis treats amyloidosis itself, removes amyloid deposits, or prevents the disease from progressing. The available research does not establish cannabis as an alternative to disease-directed therapy.
Some of the claims linking cannabis with amyloidosis appear to come from research on Alzheimer’s disease. Alzheimer’s involves the accumulation of beta-amyloid in the brain, whereas systemic amyloidosis generally involves different proteins and disease mechanisms. These conditions should not be treated as interchangeable.
For example, a 2016 study in the Journal of Alzheimer’s Disease examined cannabinoid receptor 2 and amyloid-beta processing in genetically modified mice. The researchers found that removing the receptor increased some measures of amyloid pathology, but they also concluded that the receptor played only a minor role in the beneficial effects of a THC-and-CBD preparation. The study involved an Alzheimer’s mouse model—not people with systemic or localized amyloidosis.
Earlier work also suggested possible cannabinoid effects on Alzheimer’s-related biology. A 2004 review of the endocannabinoid system in Alzheimer’s disease described changes in cannabinoid signaling in brain tissue. Separately, laboratory research reported that THC and CBD could influence beta-amyloid fibril formation under experimental conditions. Such findings may help guide future research, but results from cells, test tubes or animals cannot demonstrate that cannabis will prevent amyloid buildup in patients.
The evidence for symptom relief is similarly limited in amyloidosis specifically. Cannabis-based medicines may help some people with selected symptoms in other conditions, but effects vary by product, dose, route of administration and the patient’s overall health. “Indica” and “sativa” labels are not reliable evidence that a particular product will treat a specific amyloidosis symptom, and there is no established cannabis strain or cannabinoid regimen for amyloidosis.
Established amyloidosis care focuses on stopping or slowing production of the protein responsible for the deposits and managing organ damage. Depending on the subtype, treatment may include chemotherapy-based medicines, targeted therapies, supportive heart or kidney care, stem-cell transplantation, dialysis or organ transplantation. The Amyloidosis Foundation’s patient information emphasizes that treatment must be tailored to the specific type of amyloid disease.
Patients considering cannabis should discuss it with their amyloidosis specialist, particularly if they have heart involvement, low blood pressure, kidney disease, liver disease, cognitive symptoms or a complex medication regimen. Cannabis should not replace treatment aimed at the underlying cause of amyloidosis. At present, cannabinoids remain an experimental area of interest for amyloid-related disease, not a proven therapy for amyloidosis.
